Nebula Genomics

ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies

Retrieved on: 
Giovedì, Giugno 22, 2023
Insurance, Barrett's esophagus, Nebula, GCC, Public, Esophageal cancer, ThinkEquity, Cancer, Genomics, Endoscopy, Government, EAC, Whole genome sequencing, Death, PPP, Nebula Genomics, Gold, Dysplasia, GDP, Data, Investment, Laboratory, Patient, Medicine, WGS, Prophase, AI, Gulf Cooperation Council, Health, United Arab Emirates, Disease, Biopsy, Drug, Pharmaceutical industry

Garden City, NY, June 22, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today unveiled its mission to develop its diverse business units in the MENA region and in particular, the Gulf Cooperation Council (“GCC”) – a robust alliance of six Arab states in the Persian Gulf region, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. ProPhase aims to expand its business and form potential alliances throughout this vast region, focused on further advancing their state of the art healthcare markets.

Key Points: 
  • ProPhase aims to expand its business and form potential alliances throughout this vast region, focused on further advancing their state of the art healthcare markets.
  • ProPhase has onboarded ThinkEquity and Al Ramz as advisors to navigate these strategic initiatives.
  • "We are dedicated to unlocking potential partnerships and exploiting our advanced technology in the region," says Ted Karkus, CEO of ProPhase Labs.
  • Alongside its genomics approach, ProPhase Labs is in active discussions to partner and introduce its BE-SMART Esophageal Cancer Test to the MENA region.

ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023

Retrieved on: 
Mercoledì, Giugno 7, 2023
Diamond, Prophase, Nebula Genomics, Genomics, Vaccine

Garden City, NY, June 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Tuesday, June 13th at 1:00 pm Eastern time.

Key Points: 
  • Garden City, NY, June 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Tuesday, June 13th at 1:00 pm Eastern time.
  • Ted Karkus, Chairman and CEO of ProPhase Labs, will host a virtual investor presentation followed by a question & answer session.
  • At the same time, we are building out a world class genomics lab to complement our high complexity molecular lab and clinical lab.
  • I look forward to providing an overview next Tuesday on many of these initiatives that are making significant progress at ProPhase.”

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023

Retrieved on: 
Giovedì, Maggio 11, 2023
Exercise, HRSA, Heart, Omicron, CPT, Dana–Farber Cancer Institute, Harvard University, Internet, Genomics, COVID-19, Diagnosis, Medicine, Research, Absorption, Doctor of Philosophy, Sale, Whole genome sequencing, Public expenditure, Eurofins Scientific, CLIA, Baylor University, Nebula Genomics, EBITDA, Acquisition, Collection, KUMC, Corporation, Hospital Insurance and Diagnostic Services Act, WGS, Growth, Prophase, FDM, Galway-Mayo Institute of Technology, Three Months, Food, Creative industries, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Antibiotics, Security (finance), MD

Garden City, NY, May 11, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2023.

Key Points: 
  • Financial highlights for the three months ended March 31, 2023, include the following:
    Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022.
  • Adjusted EBITDA of $3.1 million for the three months ended March 31, 2023, as compared to adjusted EBITDA of $14.6 million for the three months ended March 31, 2022.
  • For the three months ended March 31, 2023, net revenue was $19.3 million as compared to $47.5 million for the three months ended March 31, 2022.
  • Diagnostic services costs for the three months ended March 31, 2023 were $1.2 million compared to $4.7 million for the three months ended March 31, 2022.

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023

Retrieved on: 
Venerdì, Aprile 28, 2023
Therapy, Coronavirus, COVID-19, Genomics, COVID-19 testing, Nebula Genomics, Inc., Growth, Prophase, Pharmaceutical industry

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus, CEO, has been named one of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023.

Key Points: 
  • Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus, CEO, has been named one of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023.
  • The annual listing represents dynamic healthcare leaders redefining the world with their innovative products and leadership.
  • Mr. Karkus was recognized by Inc Magazine for his visionary leadership in the healthcare industry, as well as his dedication to driving innovation and improving patient outcomes.
  • Mr. Karkus commented, “I am honored to be recognized by Inc Magazine as one of the 10 Most Innovative Healthcare Leaders to Watch for 2023.

ProPhase Labs Announces Launch of Redesigned Corporate Website

Retrieved on: 
Martedì, Aprile 25, 2023
TK, Growth, Prophase, Nebula Genomics, Genomics

Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its newly redesigned corporate website showcasing the company's diverse portfolio of subsidiaries and offerings, which include Nebula Genomics, ProPhase Diagnostics, ProPhase BioPharma, Pharmaloz Manufacturing, Inc., and TK Supplements.

Key Points: 
  • Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its newly redesigned corporate website showcasing the company's diverse portfolio of subsidiaries and offerings, which include Nebula Genomics, ProPhase Diagnostics, ProPhase BioPharma, Pharmaloz Manufacturing, Inc., and TK Supplements.
  • "We are excited to unveil our new website, which better reflects our company's diverse business units," said Ted Karkus, ProPhase Labs' Chief Executive Officer.
  • "We believe several of our subsidiaries have significant underlying value, are already experiencing significant growth and have multi-billion dollar potential.
  • The redesigned website allows us to showcase our offerings and communicate our bold vision as a next-generation biotech, genomics and diagnostics company."

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

Retrieved on: 
Martedì, Marzo 28, 2023
HRSA, Insurance, Nebula, LDT, Food, Omicron, Mayo Clinic, CPT, LB-1, Dana–Farber Cancer Institute, Stanford University, Internet, Genomics, COVID-19, University, Cancer, Diagnosis, Wall Street, Research, Absorption, COVID-19 testing, Sale, EAC, Public expenditure, Dementia, Nebula Genomics, EBITDA, RUO, Collection, Corporation, Medicine, Growth, Prophase, Hospital Insurance and Diagnostic Services Act, LB-2, Inflammation, Cryptocurrency, Pharmaceutical industry, Antibiotics

Garden City, NY, March 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today reported its financial and operational results for the year ended December 31, 2022.

Key Points: 
  • Financial highlights for the full year ended December 31, 2022, include the following:
    Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%.
  • Adjusted EBITDA of $38.6 million for the year ended December 31, 2022, as compared to adjusted EBITDA of $18.1 million for the year ended December 31, 2021.
  • For the year ended December 31, 2022, our overall gross margin was 57.6% as compared to 53.1% for the year ended December 31, 2021.
  • Research and development costs for the year ended December 31, 2022 were $0.7 million as compared to $0.5 million for the year ended December 31, 2021.

ProPhase Labs Announces New $6 Million Stock Repurchase Program

Retrieved on: 
Mercoledì, Marzo 15, 2023
EAC, LB-1, CLIA, Dana–Farber Cancer Institute, WGS, CPT, COVID-19 testing, Mayo Clinic, Genomics, Prophase, Nebula Genomics, Share repurchase, LDT, Insurance, COVID-19, Growth, Knowledge, Whole genome sequencing, OTC, Pharmaceutical industry, Security (finance)

Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.

Key Points: 
  • Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs’ common stock.
  • During the past six months, between purchasing stock in the open stock market and retiring shares from stock option exercises, the Company retired a total of 1.2 million shares of common stock.
  • The Board of Directors of the Company will re-evaluate the program from time to time and may authorize adjustments to its terms.
  • The Company expects to utilize its existing funds to fund repurchases under the repurchase program.

ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand

Retrieved on: 
Mercoledì, Febbraio 15, 2023
Negotiation, Nebula Genomics, Prophase, Genomics, CVS, Growth, Walmart, Fine chemical, Walgreens

To meet the growing demand for its products and services, Pharmaloz is acquiring new equipment which is expected to double its current capacity for pouch packaging by the second quarter of 2023.

Key Points: 
  • To meet the growing demand for its products and services, Pharmaloz is acquiring new equipment which is expected to double its current capacity for pouch packaging by the second quarter of 2023.
  • Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022.
  • Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “We are currently operating at full-capacity at Pharmaloz.
  • Pharmaloz continues to be a strong backbone to the ProPhase family of companies, with promising growth potential as we further scale production capacity to meet increasing customer demand.

Global Nutrigenomics Market Report 2022 to 2035: Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Dicembre 2, 2022
Fitness & Nutrition, Health, Geography, Saliva, Degenerative disease, Research, Infection, Blood, Nutritional genomics, Nebula Genomics, Food intolerance, Element, Malnutrition, Type, Pharmaceutical industry

The "Nutrigenomics Market by Type of Sample, Type of Sample Collection Method and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nutrigenomics Market by Type of Sample, Type of Sample Collection Method and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current landscape and future potential of the nutrigenomics focused companies.
  • The study features an in-depth analysis, highlighting the capabilities of nutrigenomics focused companies.
  • How is the current and future market opportunity likely to be distributed across key segments?

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Retrieved on: 
Mercoledì, Novembre 30, 2022
Marketing, COVID-19, Growth, EST, COVID-19 testing, Dana–Farber Cancer Institute, OTC, Polymerase chain reaction, Laboratory, Chromosome, Food, Genomics, Gene, DNA, Indian stock exchange, Institution, Prophase, PIM, Inherited disorders of trafficking, CLIA, University, PCR, Planet, Dietary supplement, FDM, Nebula Genomics, Dana, Research, RT-PCR, Severe acute respiratory syndrome coronavirus 2, LB-1, Acquisition, TK, Video game, Vaccine

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.

Key Points: 
  • GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.